IMPORTANCE Access to appropriate prescription medications, use of inappropriate or ineffective treatments, and adverse drug events are public health concerns among US children and adolescents.
M onitoring trends in use of prescription medications among children and adolescents provides insights on several important public health concerns, such as shifting disease burden, changes in access to health care and medicines, increases in the adoption of appropriate therapies, and decreases in use of inappropriate or ineffective treatments. Adverse drug events, particularly involving antibiotics, psychotropics, opioids, and cold and cough medications, are also a concern. [1] [2] [3] [4] [5] Since the 2009 publication of population-based, age-specific prescription medication trends among US children, 6 patterns of use may have changed because of adoption of new clinical practice guidelines, growing concerns about childhood obesity-related health conditions such as diabetes and hypertension, and increased awareness of antibiotic resistance. This study provides nationally representative estimates and trends in prescription medication use overall and by common therapeutic classes among US children and adolescents from 1999 to 2014.
Methods
The National Health and Nutrition Examination Survey (NHANES) is a nationally representative cross-sectional survey designed to monitor the health and nutritional status of the civilian, noninstitutionalized US population and has been conducted continuously in 2-year cycles since 1999. 7 Data from the 2013-2014 cycle are the most recent prescription medication data available. The interview response rate for children and adolescents through age 19 years was 89.2% in 1999-2002 and 80.1% in 2011-2014. 8 NHANES participants 18 years or older provided written consent, whereas parental permission was obtained for those younger than 18 years; children and adolescents aged 7 to 17 years also provided documented assent. NHANES was approved by the National Center for Health Statistics research ethics review board. Home face-to-face interviews were conducted throughout each year. Participants 16 years or older answered questions about prescription medication use themselves; for participants younger than 16 years and those not able to answer questions themselves, a proxy respondent (usually a parent) provided this information. During the interview, survey participants were asked if they had taken any prescription medication in the past 30 days. If "yes," the interviewer recorded the names of up to 20 prescription medications taken in the last 30 days directly from the medication container (eg, bottle, vial, inhaler, blister pack, paperboard box). If the container was not available, the interviewer recorded the medication name as reported by the participant. In 2013-2014, the interviewer could record the medication name using the participant's prescription documentation printed at the pharmacy ("printout") if the medication container was not available. The medication name was matched to the brand or generic name in the Multum Lexicon Plus drug database and converted to the standard drug name. 9 Any medications reported that were available only as an over-the-counter product during the 2-year survey cycle were excluded. The prevalence of use of any prescription medication and 2 or more prescription medications were evaluated for 2011-2012 and 2013-2014 combined, by age group (0-23 months, 2-5 years, 6-11 years, and 12-19 years), sex, race and Hispanic origin, household income to poverty ratio, education level of the household head, insurance status, and current health status, because previous studies have shown different patterns of prescription medication use by these characteristics. 6, 10, 11 Information on race and Hispanic origin were selfreported and categorized as non-Hispanic white, nonHispanic black, Mexican American, Hispanic (including Mexican American and other Hispanic participants), non-Hispanic Asian, or other (including multiple races). Participants categorized as "other" were included in analyses but were not reported separately. Income to poverty ratio is the ratio of household income to poverty level accounting for inflation and household size and was categorized as less than 1, 1 to less than 2, 2 to less than 3, 3 to less than 4, and 4 or greater (eg, 2 indicates an income 2 times the poverty level). Education level of the household head characterized the socioeconomic status of the household and was categorized as less than a high school degree, high school degree, some college, or college degree or higher. Self-reported insurance status was categorized as insured (including public and private sources) or uninsured.therapeutic classes were created (eTable in the Supplement): antibiotics (oral only), asthma medications, 14 attention-deficit/ hyperactivity disorder (ADHD) medications, 15 antihypertensive agents, and narcotic-containing analgesics. These classes were added because of their particular relevance to child and adolescent heath, public health priorities, and/or clinical practice guidelines [16] [17] [18] [19] [20] [21] and were created by either separating certain medications from a broader class (eg, antibiotics were in the same therapeutic class as all other anti-infective agents) or by grouping together medications from different therapeutic classes. Because many medical conditions affect youth at specific ages, use of prescription medication by age group was examined. Individual prescription medications or therapeutic subclasses selected for presentation were reported by at least 10 children or adolescents during at least 2 of the 4-year periods for the age group presented. Prevalence of contraceptive use was estimated in girls only.
Statistical Analysis
Data were aggregated over 4-year periods to provide adequate sample size for estimating small proportions. All analyses used NHANES interview sample weights that adjust for nonresponse, noncoverage, and unequal probabilities of selection; all estimates and 95% CIs were weighted to be nationally representative. Standard errors of prevalences were estimated using Taylor series linearization, and 95% CIs were constructed using the method of Korn and Graubard. 22 Trend tests for prevalence of prescription medication use in 2011-2014 across categories of age, education level of the household head, household income, and current health status were performed using linear regression by including these as continuous variables. Differences in prevalence by sex, race and Hispanic origin, and insurance status were evaluated using Pearson χ 2 test. Pairwise differences in prevalence by race and Hispanic origin were evaluated using a 2-sided t test. Linear time trends in prevalence were calculated using linear regression models, in which the 2-year NHANES cycle was modeled as a continuous variable. The linear regression estimate for the 2-year cycle (β) can be interpreted as the average percentage point change every 2 years; the 95% CI and P value for this estimate were also calculated. Stated increasing or decreasing linear trends were significant at P < .05 (2-sided).
Trends for a large number of therapeutic classes and individual and prescription medications are presented. No adjustments were made for multiple comparisons, but the magnitude of the trend (β) and 95% CI are presented in addition to the P value to help guide interpretation. Patterns of prescription medication use should be considered in the context of use of related therapeutic classes and among different age groups. R version 3.4.1 23 was used for data management, and analyses were performed using the R "survey" package 24 to account for the complex sample design.
Results
The sample comprised 38 277 children and adolescents aged 0 to 19 years (mean age, 10 years; 49% girls) over the period b P value for trend using linear regression.
c P value calculated using Pearson χ 2 test with Rao-Scott second-order correction.
d Categories "other Hispanic" and "other" not shown; χ 2 and t tests compared mutually exclusive categories: non-Hispanic white, non-Hispanic black, Hispanic, and non-Hispanic Asian.
e Significantly different from non-Hispanic white youth (P < .05).
f Includes Mexican American.
g Significantly different from non-Hispanic black youth (P < .05).
h Ratio of family income to poverty level specific to the survey year (eg, 2 indicates a household income of 2 times the poverty level).
i Fewer than 8600 participants because of missing data.
j Education level of head of household. Abbreviations: ADHD, attention-deficit/hyperactivity disorder; CNS, central nervous system; H 2 , histamine H 2 -receptor; NA, not available; SNRI, selective norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.
a Source: National Center for Health Statistics, National Health and Nutrition Examination Survey, 1999-2014. Prevalence estimates are weighted to account for differential probabilities of selection and survey nonresponse. Individual prescription medications or therapeutic subclasses presented in this table were reported by at least 10 children or adolescents during at least 2 of the 4-y periods.
b The estimate (β), 95% CI, and P value were calculated using linear regression models that included the National Health and Nutrition Examination Survey 2-y cycle as a continuous variable. The estimate (β) can be interpreted as the average biannual percentage point change in prevalence.
c Estimate may be unreliable because of relative standard error greater than 30% but less than 40%. Among children aged 0 to 23 months, all antibiotic use decreased from 15.5% to 7.6% (β = −1.12 percentage points every 2 years [95% CI, −1.62 to −0.61]; P < .001) and specifically for amoxicillin and amoxicillin/clavulanate ( Table 4) . Use of upper respiratory combination medications also decreased from 4.3% to 1.1% (β = −0.53 percentage points every 2 years [95% CI, −0.79 to −0.27]; P < .001). However, no statistically significant linear trends were observed among other therapeutic classes, including antihistamines, asthma medications, and topical agents.
Among children aged 2 to 5 years, use of inhaled corticosteroids increased from 1.2% to 2.1% (β = 0.20 percentage points every 2 years [95% CI, 0.02 to 0.39]; P = .03), and use Table 5) . However, no statistically significant linear trends were observed among other therapeutic classes, including antibiotics, glucocorticoids, and topical agents. Among children aged 6 to 11 years, use of ADHD medications increased from 4.8% to 6.2% (β = 0.32 percentage points every 2 years [95% CI, 0.04 to 0.59]; P = .03) and specifically for amphetamines ( Table 6 ). Significant decreases in all antibiotic use occurred (6.1% to 2.7%, β = −0.52 percentage points every 2 years [95% CI, −0.91 to −0.14]; P = .009) and specifically for amoxicillin. Antihistamine use decreased from 4.8% to 3.0% (β = −0.27 percentage points every 2 years [95% CI, −0.51 to −0.02]; P = .04), and antipsychotic use increased from 0.5% to 1.2% (β = 0.13 percentage points every 2 years [95% CI, 0.04 to 0.22]; P = .006). Asthma medication use increased from 4.6% to 7.6% (β = 0.50 percentage points every 2 years [95% CI, 0.16 to 0.83]; P = .004) and specifically for montelukast and inhaled corticosteroids. Use of proton pump inhibitors and dermatologic agents increased from 0.1% to 0.7% (β = 0.10 percentage points every 2 years [95% CI, 0.02 to 0.19]; P = .02) and 0.5% to 1.2% (β = 0.11 percentage points every 2 years [95% CI, 0.03 to 0.20]; P = .009), respectively, and use of upper respiratory combination medications decreased from 1.8% to 0.6% (β = −0.21 percentage points every 2 years [95% CI, −0.36 to −0.06]; P = .007). However, no statistically significant linear trends were observed among other therapeutic classes, including anticonvulsants; antidepressants; and anxiolytics, sedatives, and hypnotics.
Among adolescents aged 12 to 19 years, use of centrally acting antiadrenergic agents (clonidine and guanfacine) increased from 0.1% to 0.9% (β = 0.13 percentage points every 2 years [95% CI, 0.06 to 0.20]; P < .001), but statistically significant linear trends were not observed in central nervous system stimulants or in ADHD medications overall ( Table 7) . Significant decreases in all antibiotic use from 8.2% b The estimate (β), 95% CI, and P value were calculated using linear regression models that included the National Health and Nutrition Examination Survey 2-y cycle as a continuous variable. The estimate (β) can be interpreted as the average percentage point change in prevalence every 2 y.
c Estimate may be unreliable because of relative standard error greater than 30% but less than 40%.
d Estimate may be unreliable because of relative standard error greater than 50%.
e Estimate may be unreliable because of relative standard error greater than 40% but less than 50%.
f Estimate may be unreliable because of unweighted number less than 10. 
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Discussion
In 2011-2014, 21.9% of US children and adolescents used any prescription medication in the prior month, and 8.5% used 2 or more prescription medications. The prevalence of using any medication and 2 or more medications varied by age, Abbreviations: ADHD, attention-deficit/hyperactivity disorder; CNS, central nervous system; NA, not available; SNRI, selective norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor. Abbreviations: ADHD, attention-deficit/hyperactivity disorder; CNS, central nervous system; NA, not available; SNRI, selective norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor. Trends in prevalence of ADHD medication use from 1999-2002 to 2011-2014 in children aged 6 to 11 years and in adolescents aged 12 to 19 years varied. Use of ADHD medications increased among children aged 6 to 11 years and specifically the use of amphetamines. Among adolescents, there were no statistically significant linear trends in overall use of ADHD medications or central nervous system stimulants, but use of centrally acting antiadrenergic agents (clonidine and guanfacine), commonly used to treat ADHD, increased. New ADHD medications, including lisdexamfetamine and the selective norepinephrine reuptake inhibitor atomoxetine, were introduced during the study period, and guanfacine and clonidine were first approved to treat ADHD in 2009 and 2010.
Antibiotic use in children and adolescents decreased by almost half between 1999-2002 and 2011-2014, predominantly in amoxicillin-containing antibiotics and cephalosporins. Decreases were significant in all age groups except children aged 2 to 5 years. Decreases in antibiotic use among children and adolescents have been previously reported using NHANES 25 and other data sources. [26] [27] [28] Children aged 0 to 23 months were the only age group to show decreasing medication use over time, and antibiotics constituted a relatively large proportion of medications used in this age group. This study adds nationally representative age-specific trends for common individual antibiotic classes and provides information for continued monitoring of antibiotic use in children and adolescents to inform programs such as the Centers for Disease Control and Prevention Be Antibiotics Aware: Smart Use, Best Care educational effort, 16 which promotes awareness of antibiotic resistance and the importance of appropriate antibiotic prescribing. This study also showed an increase in use of antihypertension medications among adolescents. There was no statistically significant linear trend in use of antidiabetic agents. An expert panel has provided recommendations to optimize cardiovascular health of children and adolescents, including recommendations for pharmacologic and nonpharmacologic treatment of hypertension and diabetes. 19 While the expert panel also provided recommendations for interventions to reduce dyslipidemia, too few children and adolescents reported taking cholesterol-lowering medications to present prevalence estimates. Antipsychotic use increased in children aged 6 to 11 years but not in adolescents. A previous study showed increases in the proportion of outpatient visits that included a prescription of antipsychotics from 1993-1998 to 2005-2009 in both children and adolescents. 29 Another study of data from 2009
showed that among claims for antipsychotic prescriptions in children aged 7 to 12 years with a psychiatric diagnosis, ADHD was the most common diagnosis, followed by disruptive behavioral disorders and autism and other pervasive developmental disorders. 30 Patterns of asthma medication use were consistent with previously reported trends in asthma prevalence, which increased until a plateau in 2009, with subsequent decreases in children but steady increasing prevalence among adolescents. 31 The overall increase in use of montelukast may reflect its introduction in 1998 and incorporation into treatment regimens. The effectiveness and safety of cough and cold medications have been called into question.
3,32 NHANES did not collect data on most over-the-counter medications. While certain upper respiratory combination medications (eg, those containing codeine) could be obtained by prescription only, many formulations were available both by prescription and over the counter (eTable in the Supplement). Moreover, certain antihistamines became available over the counter during the study period. This study showed a marked decrease in the use of prescription upper respiratory combination medications and prescription antihistamines overall; decreases also occurred within each age category. NHANES has several strengths for surveillance of trends in prescription medication use among children and adolescents. NHANES data are nationally representative and included the medication name and linkage to Multum Lexicon Plus therapeutic drug categories. Recording the names of prescription drugs from the medication container by trained personnel strengthened validity and completeness. This study provided more recent estimates over a wider age range then those published using the Slone Survey, a nationally representative telephone survey that included 2857 children younger than 12 years from 1998-2007. 6 NHANES data have also been used for surveillance of prescription medication trends among adults 20 years or older, 33 and Health, United
States periodically publishes estimates of prescription medication use using NHANES data by therapeutic category.
34
Limitations
This study has several limitations. First, NHANES did not capture dosages, formulations, or frequency of use, nor did it collect data on most over-the-counter medications. Second, although survey staff worked to capture all prescription medication use, underreporting is possible. Third, because of small sample sizes, estimates could be calculated for only the most common therapeutic classes of prescription medications and individual medications. Interpreting trends in outcomes with low prevalence is difficult in complex surveys, including NHANES, because of uncertainty in the distribution of the outcome and appropriate methods for statistical testing. Large samples are desirable for such analyses, and strategies could include combining NHANES cycles and avoiding analysis of small subgroups. Fourth, because there was no adjustment for multiple comparisons, there is the potential for type I error.
Conclusions
In this study of US children and adolescents based on a nationally representative survey, estimates of prescription medication use showed an overall decrease in use of any medication from 1999-2014. The prevalence of asthma medication, ADHD medication, and contraceptive use increased among certain age groups, whereas use of antibiotics, antihistamines, and upper respiratory combination medications decreased.
